{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:50:06Z","timestamp":1790196606553,"version":"4.1.0"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007880","name":"Johns Hopkins University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007880","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01EY031097"],"award-info":[{"award-number":["R01EY031097"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P41EB028239"],"award-info":[{"award-number":["P41EB028239"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ajo.2024.12.010","type":"journal-article","created":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T02:24:16Z","timestamp":1734747856000},"page":"518-533","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Suprachoroidal Delivery of Viral and Nonviral Vectors for Treatment of Retinal and Choroidal Vascular Diseases"],"prefix":"10.1016","volume":"277","author":[{"given":"Yeongseo","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2531-8229","authenticated-orcid":false,"given":"Peter A.","family":"Campochiaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4176-3808","authenticated-orcid":false,"given":"Jordan J.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.ajo.2024.12.010_bib0001","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Eng J Med"},{"issue":"14","key":"10.1016\/j.ajo.2024.12.010_bib0002","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N Eng J Med"},{"issue":"12","key":"10.1016\/j.ajo.2024.12.010_bib0003","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal Aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.ajo.2024.12.010_bib0004","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.ophtha.2017.03.057","article-title":"Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial","volume":"124","author":"Dugel","year":"2017","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.ajo.2024.12.010_bib0005","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1016\/j.ophtha.2009.04.023","article-title":"Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study","volume":"116","author":"Nguyen","year":"2009","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2024.12.010_bib0006","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema. results from 2 phase III randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.ajo.2024.12.010_bib0007","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.ophtha.2011.02.022","article-title":"Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study","volume":"118","author":"Brown","year":"2011","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.ajo.2024.12.010_bib0008","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.ophtha.2011.02.038","article-title":"Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: 12-month outcomes of a phase III study","volume":"118","author":"Campochiaro","year":"2011","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.ajo.2024.12.010_bib0009","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","article-title":"Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration","volume":"99","author":"Holz","year":"2015","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2024.12.010_bib0010","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ophtha.2017.10.010","article-title":"Real-world vision in age-related macular degeneration patients treated with single anti-VEGF drug type for 1 year in the IRIS registry","volume":"125","author":"Rao","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2024.12.010_bib0011","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.oret.2019.05.017","article-title":"Visual acuity outcomes and anti-vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients: a real-world analysis of 49,485 eyes","volume":"4","author":"Ciulla","year":"2020","journal-title":"Ophthalmol Retina"},{"issue":"2","key":"10.1016\/j.ajo.2024.12.010_bib0012","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/bjophthalmol-2020-315933","article-title":"Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28,658 patient eyes","volume":"105","author":"Ciulla","year":"2021","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2024.12.010_bib0013","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","article-title":"Five-year outcomes with anti\u2013vascular endothelial growth factor treatment of neovascular age-related macular degeneration. The comparison of age-related macular degeneration treatments trials","volume":"123","author":"Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group","year":"2016","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ajo.2024.12.010_bib0014","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.ophtha.2018.01.004","article-title":"Development and course of scars in the comparison of age-related macular degeneration treatments trials","volume":"125","author":"Daniel","year":"2018","journal-title":"Ophthalmology"},{"issue":"6372","key":"10.1016\/j.ajo.2024.12.010_bib0015","doi-asserted-by":"crossref","first-page":"eaan4672","DOI":"10.1126\/science.aan4672","article-title":"Gene therapy comes of age","volume":"359","author":"Dunbar","year":"2018","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.ajo.2024.12.010_bib0016","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/j.ymthe.2020.06.029","article-title":"Gene therapy intervention in neovascular eye disease: a recent update","volume":"28","author":"Lin","year":"2020","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.ajo.2024.12.010_bib0017","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11095-018-2554-7","article-title":"Pharmaceutical development of AAV-based gene therapy products for the eye","volume":"36","author":"Rodrigues","year":"2019","journal-title":"Pharm Res"},{"issue":"15","key":"10.1016\/j.ajo.2024.12.010_bib0018","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1080\/14656566.2019.1636031","article-title":"Innovative therapies for neovascular age-related macular degeneration","volume":"20","author":"Al-Khersan","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ajo.2024.12.010_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114770","article-title":"Polymer-and lipid-based nanocarriers for ocular drug delivery: current status and future perspectives","volume":"196","author":"Han","year":"2023","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.ajo.2024.12.010_bib0020","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.3389\/fphar.2019.01076","article-title":"Outcome measures used in ocular gene therapy trials: a scoping review of current practice","volume":"10","author":"Jolly","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ajo.2024.12.010_bib0021","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.2147\/OPTH.S364200","article-title":"Ocular gene therapy: a literature review with special focus on immune and inflammatory responses","volume":"16","author":"Ghoraba","year":"2022","journal-title":"Clin Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2024.12.010_bib0022","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.3390\/biom11081135","article-title":"The ocular gene delivery landscape","volume":"11","author":"Sahu","year":"2021","journal-title":"Biomolecules"},{"issue":"24","key":"10.1016\/j.ajo.2024.12.010_bib0023","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1056\/NEJMra0801537","article-title":"Age-related macular degeneration","volume":"358","author":"Jager","year":"2008","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ajo.2024.12.010_bib0024","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/mt.2009.181","article-title":"Inner limiting membrane barriers to AAV-mediated retinal transduction from the vitreous","volume":"17","author":"Dalkara","year":"2009","journal-title":"Mol Ther"},{"issue":"10","key":"10.1016\/j.ajo.2024.12.010_bib0025","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.135112","article-title":"In vivo-directed evolution of adeno-associated virus in the primate retina","volume":"5","author":"Byrne","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.ajo.2024.12.010_bib0026","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11095-008-9745-6","article-title":"Investigating the movement of intravitreal human serum albumin nanoparticles in the vitreous and retina","volume":"26","author":"Kim","year":"2009","journal-title":"Pharm. Res."},{"issue":"10","key":"10.1016\/j.ajo.2024.12.010_bib0027","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1167\/iovs.05-0165","article-title":"Vitreous: a barrier to nonviral ocular gene therapy","volume":"46","author":"Peeters","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2024.12.010_bib0028","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1023\/A:1023238530504","article-title":"Vitreous is a barrier in nonviral gene transfer by cationic lipids and polymers","volume":"20","author":"Pitk\u00e4nen","year":"2003","journal-title":"Pharm Res"},{"key":"10.1016\/j.ajo.2024.12.010_bib0029","first-page":"1760","article-title":"Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential","volume":"14","author":"Li","year":"2008","journal-title":"Mol Vis"},{"issue":"5","key":"10.1016\/j.ajo.2024.12.010_bib0030","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1167\/iovs.17-22494","article-title":"Humoral immune response after intravitreal but not after subretinal AAV8 in primates and patients","volume":"59","author":"Reichel","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ajo.2024.12.010_bib0031","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s40123-020-00230-4","article-title":"Intravitreal injections with vascular endothelial growth factor inhibitors: a practical approach","volume":"9","author":"Petri","year":"2020","journal-title":"Ophthalmol Ther"},{"issue":"7","key":"10.1016\/j.ajo.2024.12.010_bib0032","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature","volume":"27","author":"Ghasemi Falavarjani","year":"2013","journal-title":"Eye"},{"issue":"3","key":"10.1016\/j.ajo.2024.12.010_bib0033","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/ICU.0000000000000850","article-title":"Complications of intravitreal injections: 2022","volume":"33","author":"Patel","year":"2022","journal-title":"Curr Opin Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2024.12.010_bib0034","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1089\/jop.2019.0126","article-title":"Suprachoroidal delivery of viral and nonviral gene therapy for retinal diseases","volume":"36","author":"Kansara","year":"2020","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.ajo.2024.12.010_bib0035","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.preteyeres.2014.08.001","article-title":"Vector platforms for gene therapy of inherited retinopathies","volume":"43","author":"Trapani","year":"2014","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ajo.2024.12.010_bib0036","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s11095-010-0271-y","article-title":"Suprachoroidal drug delivery to the back of the eye using hollow microneedles","volume":"28","author":"Patel","year":"2011","journal-title":"Pharm Res"},{"issue":"8","key":"10.1016\/j.ajo.2024.12.010_bib0037","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1167\/iovs.12-9872","article-title":"Targeted administration into the suprachoroidal space using a microneedle for drug delivery to the posterior segment of the eye","volume":"53","author":"Patel","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"10.1016\/j.ajo.2024.12.010_bib0038","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.3390\/ph16091241","article-title":"Suprachoroidal injection: a novel approach for targeted drug delivery","volume":"16","author":"Wu","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"13-14","key":"10.1016\/j.ajo.2024.12.010_bib0039","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1089\/hum.2020.281","article-title":"Host immune responses after suprachoroidal delivery of AAV8 in nonhuman primate eyes","volume":"32","author":"Chung","year":"2021","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.ajo.2024.12.010_bib0040","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.omtm.2020.01.002","article-title":"Suprachoroidal and subretinal injections of AAV using transscleral microneedles for retinal gene delivery in nonhuman primates","volume":"16","author":"Yiu","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"6","key":"10.1016\/j.ajo.2024.12.010_bib0041","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/17425247.2021.1867532","article-title":"Biomechanics of suprachoroidal drug delivery: from benchtop to clinical investigation in ocular therapies","volume":"18","author":"Hancock","year":"2021","journal-title":"Expert Opin Drug Deliv"},{"issue":"11","key":"10.1016\/j.ajo.2024.12.010_bib0042","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1172\/JCI129085","article-title":"AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression","volume":"129","author":"Ding","year":"2019","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.ajo.2024.12.010_bib0043","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.ajo.2024.12.010_bib0044","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40259-023-00629-y","article-title":"AAV-based strategies for treatment of retinal and choroidal vascular diseases: advances in age-related macular degeneration and diabetic retinopathy therapies","volume":"38","author":"Castro","year":"2024","journal-title":"BioDrugs"},{"issue":"12","key":"10.1016\/j.ajo.2024.12.010_bib0045","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/s41434-021-00243-z","article-title":"Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions","volume":"28","author":"Riyad","year":"2021","journal-title":"Gene Therapy"},{"issue":"4","key":"10.1016\/j.ajo.2024.12.010_bib0046","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat Rev Genet"},{"issue":"1","key":"10.1016\/j.ajo.2024.12.010_bib0047","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Sig Transduct Target Ther"},{"issue":"4","key":"10.1016\/j.ajo.2024.12.010_bib0048","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-associated virus (AAV) as a vector for gene therapy","volume":"31","author":"Naso","year":"2017","journal-title":"BioDrugs"},{"key":"10.1016\/j.ajo.2024.12.010_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100915","article-title":"Immune responses to retinal gene therapy using adeno-associated viral vectors\u2013implications for treatment success and safety","volume":"83","author":"Bucher","year":"2021","journal-title":"Prog Retin Eye Res"},{"issue":"2","key":"10.1016\/j.ajo.2024.12.010_bib0050","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/13816810802626399","article-title":"RPE65: role in the visual cycle, human retinal disease, and gene therapy","volume":"30","author":"Cai","year":"2009","journal-title":"Ophthalmic Genet"},{"key":"10.1016\/j.ajo.2024.12.010_bib0051","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(24)00310-6","article-title":"Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1\/2a dose-escalation study","volume":"403","author":"Campochiaro","year":"2024","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ajo.2024.12.010_bib0052","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41434-021-00233-1","article-title":"Proteosomal degradation impairs transcytosis of AAV vectors from suprachoroidal space to retina","volume":"28","author":"Ding","year":"2021","journal-title":"Gene Ther"},{"issue":"22","key":"10.1016\/j.ajo.2024.12.010_bib0053","doi-asserted-by":"crossref","first-page":"7827","DOI":"10.1073\/pnas.0802866105","article-title":"Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses","volume":"105","author":"Zhong","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.ajo.2024.12.010_bib0054","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/mt.2010.234","article-title":"Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina","volume":"19","author":"Petrs-Silva","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.ajo.2024.12.010_bib0055","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.chom.2011.10.014","article-title":"Adeno-associated virus 2 infection requires endocytosis through the CLIC\/GEEC pathway","volume":"10","author":"Nonnenmacher","year":"2011","journal-title":"Cell Host Microbe"},{"issue":"3","key":"10.1016\/j.ajo.2024.12.010_bib0056","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ymthe.2005.11.007","article-title":"AAV transcytosis through barrier epithelia and endothelium","volume":"13","author":"Di Pasquale","year":"2005","journal-title":"Mol Ther"},{"key":"10.1016\/j.ajo.2024.12.010_bib0057","unstructured":"Pitcher JD. Suprachoroidal delivery of investigational ABBV-RGX-314 for neovascular AMD: results from the phase II AAVIATE\u00ae study; 2024. https:\/\/www.regenxbio.com\/getattachment\/09eea7b5-fa2a-4474-90e2-19d8670a6f6f\/ABBV-RGX-314-SCSwAMD-AAVIATE_Pitcher_RHE2024_FINAL_approved-(1).pdf?lang=en-US&ext=.pdf. Accessed August 25, 2024."},{"key":"10.1016\/j.ajo.2024.12.010_bib0058","unstructured":"Barakat MR. Suprachoroidal delivery of investigational ABBV-RGX-314 for diabetic retinopathy: the Phase II ALTITUDE\u00ae Study dose levels 1 and 2: one year results; 2023. https:\/\/www.regenxbio.com\/getattachment\/9463317c-3806-4434-aa79-898162f2665a\/Barakat_03Nov23_ABBV-RGX-314-SCS-ALTITUDE-AAO-2023-FINAL_02Nov23.pdf?lang=en-US&ext=.pdf. Accessed August 25, 2024."},{"issue":"1","key":"10.1016\/j.ajo.2024.12.010_bib0059","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/mt.2009.255","article-title":"Effect of genome size on AAV vector packaging","volume":"18","author":"Wu","year":"2010","journal-title":"Mol Ther"},{"issue":"8","key":"10.1016\/j.ajo.2024.12.010_bib0060","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.ymthe.2022.06.004","article-title":"Evaluating the state of the science for adeno-associated virus integration: an integrated perspective","volume":"30","author":"Sabatino","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.ajo.2024.12.010_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113851","article-title":"Liposome composition in drug delivery design, synthesis, characterization, and clinical application","volume":"176","author":"Large","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"10.1016\/j.ajo.2024.12.010_bib0062","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ajo.2024.12.010_bib0063","doi-asserted-by":"crossref","first-page":"eadd4623","DOI":"10.1126\/sciadv.add4623","article-title":"Peptide-guided lipid nanoparticles deliver mRNA to the neural retina of rodents and nonhuman primates","volume":"9","author":"Herrera-Barrera","year":"2023","journal-title":"Sci Adv"},{"key":"10.1016\/j.ajo.2024.12.010_bib0064","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.cobme.2018.09.005","article-title":"Polymeric nucleic acid delivery for immunoengineering","volume":"7","author":"Tzeng","year":"2018","journal-title":"Curr Opin Biomed Eng"},{"issue":"6","key":"10.1016\/j.ajo.2024.12.010_bib0065","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1021\/ar7002336","article-title":"A combinatorial polymer library approach yields insight into nonviral gene delivery","volume":"41","author":"Green","year":"2008","journal-title":"Acc Chem Res"},{"issue":"10","key":"10.1016\/j.ajo.2024.12.010_bib0066","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1080\/17425247.2020.1796628","article-title":"Poly(beta-amino ester)s as gene delivery vehicles: challenges and opportunities","volume":"17","author":"Karlsson","year":"2020","journal-title":"Expert Opin Drug Deliv"},{"issue":"11","key":"10.1016\/j.ajo.2024.12.010_bib0067","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1021\/mp3004176","article-title":"Uptake and transfection with polymeric nanoparticles are dependent on polymer end-group structure, but largely independent of nanoparticle physical and chemical properties","volume":"9","author":"Sunshine","year":"2012","journal-title":"Mol Pharm"},{"issue":"11","key":"10.1016\/j.ajo.2024.12.010_bib0068","doi-asserted-by":"crossref","first-page":"10472","DOI":"10.1021\/acsami.8b20206","article-title":"Reducible Branched Ester-Amine Quadpolymers (rBEAQs) codelivering plasmid DNA and RNA oligonucleotides enable CRISPR\/Cas9 genome editing","volume":"11","author":"Rui","year":"2019","journal-title":"ACS Appl Mater Interfaces"},{"issue":"2","key":"10.1016\/j.ajo.2024.12.010_bib0069","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1021\/acs.molpharmaceut.8b00963","article-title":"Differentially branched ester amine quadpolymers with amphiphilic and pH-sensitive properties for efficient plasmid DNA delivery","volume":"16","author":"Wilson","year":"2019","journal-title":"Mol Pharm"},{"issue":"6","key":"10.1016\/j.ajo.2024.12.010_bib0070","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1002\/jbm.a.36033","article-title":"Continuous microfluidic assembly of biodegradable poly(beta-amino ester)\/DNA nanoparticles for enhanced gene delivery","volume":"105","author":"Wilson","year":"2017","journal-title":"J Biomed Mater Res A"},{"issue":"3","key":"10.1016\/j.ajo.2024.12.010_bib0071","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/smll.201101718","article-title":"A novel assay for quantifying the number of plasmids encapsulated by polymer nanoparticles","volume":"8","author":"Bhise","year":"2012","journal-title":"Small"},{"issue":"4","key":"10.1016\/j.ajo.2024.12.010_bib0072","doi-asserted-by":"crossref","first-page":"493","DOI":"10.4155\/tde.11.14","article-title":"Advances in polymeric and inorganic vectors for nonviral nucleic acid delivery","volume":"2","author":"Sunshine","year":"2011","journal-title":"Ther Deliv"},{"issue":"18","key":"10.1016\/j.ajo.2024.12.010_bib0073","doi-asserted-by":"crossref","first-page":"6951","DOI":"10.1021\/ja4002376","article-title":"The effect and role of carbon atoms in poly(beta-amino ester)s for DNA binding and gene delivery","volume":"135","author":"Bishop","year":"2013","journal-title":"J Am Chem Soc"},{"issue":"7","key":"10.1016\/j.ajo.2024.12.010_bib0074","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.nano.2012.01.006","article-title":"Gene delivery nanoparticles specific for human microvasculature and macrovasculature","volume":"8","author":"Shmueli","year":"2012","journal-title":"Nanomedicine"},{"issue":"5","key":"10.1016\/j.ajo.2024.12.010_bib0075","article-title":"Biodegradable polyester nanoparticle vaccines deliver self-amplifying mRNA in mice at low doses","volume":"6","author":"Wilson","year":"2023","journal-title":"Adv. Ther. (Weinh)."},{"issue":"1","key":"10.1016\/j.ajo.2024.12.010_bib0076","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1021\/bc4002322","article-title":"Differential polymer structure tunes mechanism of cellular uptake and transfection routes of poly(beta-amino ester) polyplexes in human breast cancer cells","volume":"25","author":"Kim","year":"2014","journal-title":"Bioconjug Chem"},{"issue":"1","key":"10.1016\/j.ajo.2024.12.010_bib0077","doi-asserted-by":"crossref","first-page":"eabk2855","DOI":"10.1126\/sciadv.abk2855","article-title":"High-throughput and high-content bioassay enables tuning of polyester nanoparticles for cellular uptake, endosomal escape, and systemic in vivo delivery of mRNA","volume":"8","author":"Rui","year":"2022","journal-title":"Sci Adv"},{"issue":"6","key":"10.1016\/j.ajo.2024.12.010_bib0078","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1021\/acsbiomaterials.0c00271","article-title":"Efficiency of cytosolic delivery with poly(beta-amino ester) nanoparticles is dependent on the effective pKa of the polymer","volume":"6","author":"Routkevitch","year":"2020","journal-title":"ACS Biomater Sci Eng"},{"issue":"7","key":"10.1016\/j.ajo.2024.12.010_bib0079","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/j.ymthe.2017.04.008","article-title":"A triple-fluorophore-labeled nucleic acid pH nanosensor to investigate non-viral gene delivery","volume":"25","author":"Wilson","year":"2017","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.ajo.2024.12.010_bib0080","doi-asserted-by":"crossref","first-page":"191","DOI":"10.18433\/jpps30318","article-title":"Drug targeting strategies based on charge dependent uptake of nanoparticles into cancer cells","volume":"22","author":"Saadat","year":"2019","journal-title":"J Pharm Pharm Sci"},{"issue":"45","key":"10.1016\/j.ajo.2024.12.010_bib0081","doi-asserted-by":"crossref","first-page":"44826","DOI":"10.1074\/jbc.M308643200","article-title":"Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes","volume":"278","author":"Sonawane","year":"2003","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.ajo.2024.12.010_bib0082","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.ymthe.2005.02.010","article-title":"A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer\/therapy","volume":"11","author":"Moghimi","year":"2005","journal-title":"Mol Ther"},{"issue":"5","key":"10.1016\/j.ajo.2024.12.010_bib0083","doi-asserted-by":"crossref","first-page":"e37543","DOI":"10.1371\/journal.pone.0037543","article-title":"Poly(beta-amino ester)-nanoparticle mediated transfection of retinal pigment epithelial cells in vitro and in vivo","volume":"7","author":"Sunshine","year":"2012","journal-title":"PLoS One"},{"issue":"27","key":"10.1016\/j.ajo.2024.12.010_bib0084","doi-asserted-by":"crossref","first-page":"eaba1606","DOI":"10.1126\/sciadv.aba1606","article-title":"Suprachoroidal gene transfer with nonviral nanoparticles","volume":"6","author":"Shen","year":"2020","journal-title":"Sci Adv"},{"issue":"10","key":"10.1016\/j.ajo.2024.12.010_bib0085","doi-asserted-by":"crossref","first-page":"eadl3576","DOI":"10.1126\/sciadv.adl3576","article-title":"Suprachoroidal gene transfer with nonviral nanoparticles in large animal eyes","volume":"10","author":"Shen","year":"2024","journal-title":"Sci Adv"},{"issue":"29","key":"10.1016\/j.ajo.2024.12.010_bib0086","doi-asserted-by":"crossref","first-page":"eabo6406","DOI":"10.1126\/sciadv.abo6406","article-title":"Polymeric nanoparticles for dual-targeted theranostic gene delivery to hepatocellular carcinoma","volume":"8","author":"Vaughan","year":"2022","journal-title":"Sci Adv"},{"issue":"26","key":"10.1016\/j.ajo.2024.12.010_bib0087","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2301606120","article-title":"Biodegradable lipophilic polymeric mRNA nanoparticles for ligand-free targeting of splenic dendritic cells for cancer vaccination","volume":"120","author":"Ben-Akiva","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajo.2024.12.010_bib0088","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.biomaterials.2019.04.020","article-title":"Cancer-selective nanoparticles for combinatorial siRNA delivery to primary human GBM in vitro and in vivo","volume":"209","author":"Kozielski","year":"2019","journal-title":"Biomaterials"},{"issue":"7","key":"10.1016\/j.ajo.2024.12.010_bib0089","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1021\/acs.nanolett.8b00390","article-title":"Bioreducible polymeric nanoparticles containing multiplexed cancer stem cell regulating miRNAs inhibit glioblastoma growth and prolong survival","volume":"18","author":"Lopez-Bertoni","year":"2018","journal-title":"Nano Lett"},{"issue":"30","key":"10.1016\/j.ajo.2024.12.010_bib0090","doi-asserted-by":"crossref","first-page":"7544","DOI":"10.1016\/j.biomaterials.2013.06.044","article-title":"Long-term suppression of ocular neovascularization by intraocular injection of biodegradable polymeric particles containing a serpin-derived peptide","volume":"34","author":"Shmueli","year":"2013","journal-title":"Biomaterials"},{"issue":"4","key":"10.1016\/j.ajo.2024.12.010_bib0091","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1053\/j.gastro.2023.06.028","article-title":"A novel peptide prevents enterotoxin- and inflammation-induced intestinal fluid secretion by stimulating sodium-hydrogen exchanger 3 activity","volume":"165","author":"Zachos","year":"2023","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.ajo.2024.12.010_bib0092","doi-asserted-by":"crossref","first-page":"eaay3255","DOI":"10.1126\/sciadv.aay3255","article-title":"Carboxylated branched poly(beta-amino ester) nanoparticles enable robust cytosolic protein delivery and CRISPR-Cas9 gene editing","volume":"5","author":"Rui","year":"2019","journal-title":"Sci Adv"},{"issue":"3","key":"10.1016\/j.ajo.2024.12.010_bib0093","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s40883-019-00118-1","article-title":"A combinatorial library of biodegradable polyesters enables non-viral gene delivery to post-mitotic human stem cell-derived polarized RPE monolayers","volume":"6","author":"Mishra","year":"2019","journal-title":"Regen Eng Transl Med"},{"issue":"5","key":"10.1016\/j.ajo.2024.12.010_bib0094","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1021\/nn501197v","article-title":"Biodegradable polymeric nanoparticles show high efficacy and specificity at DNA delivery to human glioblastoma in vitro and in vivo","volume":"8","author":"Guerrero-Cazares","year":"2014","journal-title":"ACS Nano"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939424005713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939424005713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T05:20:58Z","timestamp":1755235258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939424005713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":94,"alternative-id":["S0002939424005713"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2024.12.010","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suprachoroidal Delivery of Viral and Nonviral Vectors for Treatment of Retinal and Choroidal Vascular Diseases","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2024.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}